

Eventide Healthcare & Life Sciences Fund

Class I (ETIHX)

Annual Shareholder Report - June 30, 2026



Fund Overview

This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2025 to June 30, 2026. You can find additional information about the Fund at <https://www.eventidefunds.com>. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund's costs for the last year?


(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class I	\$175	1.29%

How did the Fund perform during the reporting period?

During the fiscal year, the Fund significantly outperformed the broader market. This was largely due to the outperformance of the biotech industry. After several years of struggling, biotech drew significant investor interest because of its high innovation, attractiveness as a source of M&A targets, favorable regulatory dynamics, and a differentiated correlation profile. The Fund has remained overweight the medtech and diagnostic subsectors, as well as in biotech companies in later development and commercial stages. We believe the Fund is strategically aligned to leverage the innovation in healthcare to address important unmet needs. Visit <https://www.eventidefunds.com> for more recent performance information.

How has the Fund performed over the last ten years?




The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. The Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the Fund's investment universe.

Fund Statistics	
Net Assets	\$1,789,380,256
Number of Portfolio Holdings	90
Advisory Fee	\$16,626,771
Portfolio Turnover	87%


	1 Year	5 Years	10 Years
Eventide Healthcare & Life Sciences Fund - Class I	71.76%	6.77%	14.82%
S&P Biotechnology Select Industry Index	92.00%	3.45%	11.59%
Bloomberg US 3000 Equal Weight Total Return Index	37.65%	5.85%	11.57%

What did the Fund invest in?

Industry Weighting (% of net assets)



Asset Weighting (% of total investments)



Top 10 Holdings* (% of net assets)

Holding Name	% of Net Assets
Guardant Health, Inc.	5.4%
Mirum Pharmaceuticals, Inc.	3.5%
Kymera Therapeutics, Inc.	3.2%
Abivax S.A. - ADR	2.9%
BeLite Bio Inc	2.8%
Trevi Therapeutics, Inc.	2.8%
MBX Biosciences, Inc.	2.7%
Vaxcyte, Inc.	2.7%
Cytokinetics, Inc.	2.7%
Argenx S.E. - ADR	2.6%

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

Material Fund Changes

No material changes occurred during the year ended June 30, 2026.



Eventide Healthcare & Life Sciences Fund - Class I (ETIHX)

Annual Shareholder Report - June 30, 2026

Where can I find additional information about the Fund?

Additional information is available on the Fund's website (<https://www.eventidefunds.com>), including its:

- Prospectus
- Financial information
- Holdings
- Proxy voting information



TSR-AR 063026-ETIHX